Metformin-induced cholangiohepatitis
- PMID: 21754960
- PMCID: PMC3028181
- DOI: 10.1136/bcr.09.2008.0950
Metformin-induced cholangiohepatitis
Abstract
Drug-induced cholangiohepatitis accounts for 20-50% of non-viral chronic hepatitis cases. Metformin is the most commonly prescribed oral anti-diabetic drug from the biguanide class used in treatment of overweight and obese type 2 diabetes mellitus patients. Metformin-induced cholangiohepatitis with marked elevations in serum liver transaminases and intrahepatic cholestasis has been infrequently reported. Here, we report a case of acute cholangiohepatitis after initiation of metformin treatment.
Figures
References
-
- Wood AJJ, Bailey CJ, Turner RC. Metformin. NEJM 1996; 334: 574–9 - PubMed
-
- Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Int Med 2002; 137: 25–33 - PubMed
-
- Desilets DJ, Shorr AF, Moran KA, et al. Cholestatic jaundice associated with the use of metformin. Am J Gastroenterol 2001; 96: 2257–8 - PubMed
-
- Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. Endocrine Practice 2003; 9: 307–9 - PubMed
-
- Baillieres Drug-induced cholestasis. Clin Gastroenterol 1988; 2: 423–52 - PubMed
LinkOut - more resources
Full Text Sources